Xeris Pharmaceuticals Inc. (XERS) Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol-Formulated Once-Weekly Subcutaneous Levothyroxine (XP-8121)

Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Xeris+Pharmaceuticals+Inc.+%28XERS%29+Announces+Positive+Topline+Phase+2+Clinical+Data+of+Its+Investigational+XeriSol-Formulated+Once-Weekly+Subcutaneous+Levothyroxine+%28XP-8121%29/23296374.html for the full story.